clinical significance in modifying the risk of atherosclerosis remains unclear. Background. Intraperitoneally administered insulin is regarded as the most physiological replacement therapy, leading to lower peripheral insulin concentra-Key words: CAPD, glucose metabolism; intraperitoneal tions and equal or better glycaemic control than subcu-insulin; insulin-dependent diabetes mellitus; lipoprotaneous insulin. This two-part study was undertaken teins; uraemia to evaluate the effect of CAPD, as well as the use of subcutaneous vs. intraperitoneal insulin on insulin sensitivity, glycaemic control and serum lipids in type 1 diabetes.
Introduction
Methods. Eleven patients with type 1 diabetes mellitus and chronic renal failure participated the studies. Continuous ambulatory peritoneal dialysis (CAPD) is Glycated haemoglobin ( HbA 1c ), euglycaemic hyperin-commonly used for the treatment of end-stage renal sulinaemic clamp, serum lipids, and patient well-being disease (ESRD) in diabetic patients [1 ] . CAPD has were measured. During CAPD all patients were first some advantages over haemodialysis, including steadytreated with subcutaneous insulin and then with intra-state haemodynamics and biochemistry, simple hardperitoneal insulin. The metabolic studies were repeated ware, reduced cardiovascular stress, and good blood after both treatment periods for at least 3 months. pressure control. In addition it offers the possibility Metabolic studies were performed on six of the patients for intraperitoneal insulin administration, which is also before initiation of CAPD.
theoretically the most physiological replacement Results. HbA 1c rose after the initiation of CAPD (from therapy of insulin [2 ] . Intraperitoneal insulin simulates 8.85±0.54% to 9.58±0.66%, NS ) and improved after normal insulin secretion and has been shown to changing from subcutaneous to intraperitoneally improve glycaemia [3] . Compared to subcutaneous administered insulin (from 9.49±0.43% to 8.13± insulin treatment it gives equal or better glycaemic 0.39%, P<0.01). Insulin dose increased by 15% after control [4] . Insulin sensitivity is better during CAPD initiation of CAPD and 128% after switching from than during haemodialysis therapy [5] . These observasubcutaneous to intraperitoneal insulin. Glucose dis-tions have made intraperitoneal insulin a common posal rate enhanced by 39% (P=0.05) and 14% respect-method of treatment in patients with insulin-dependent ively (P<0.01). Initiation of CAPD had no significant diabetes mellitus (IDDM ) undergoing CAPD. effects on serum lipids but intraperitoneally adminisAtherosclerosis is a major cause of morbidity and tered insulin reduced HDL cholesterol and increased mortality among diabetic subjects [6 ] . Several risk LDL/HDL ratio significantly.
factors including increased peripheral insulin concenConclusions. Intraperitoneal insulin therapy offers tration [7] and unfavourable lipid profile are involved better glycaemic control and insulin sensitivity than [6 ] . Subcutaneous insulin delivery routinely results in subcutaneous insulin. Deterioration of HbA 1c after peripheral hyperinsulinaemia. Intraperitoneal insulin initiation of CAPD while patients remained on subcu-therapy mimicking physiological insulin delivery results taneous insulin may be partly due to absorbed energy in lower peripheral insulin concentrations and a nearfrom the dialysate. Intraperitoneal insulin therapy normal portal/peripheral insulin gradient [2] . High seems to have detrimental effects on serum lipids. The cholesterol, increased low-density lipoprotein (LDL) cholesterol and increased LDL/HDL ratio correlate with increased incidence of cardiac death in patients in addition whenever necessary. Patients had adopted this toneal insulin on serum lipids vary from beneficial routine before the study and were informed to keep the [9,10] to detrimental [11, 12] . The superiority of intra- 
Subjects and methods
1179±27 and 1180±54 pmol/l (divide by 6 to get mU/l ) during the predialysis, subcutaneous, and intraperitoneal
Subjects
insulin periods respectively ( NS). Initially, plasma glucose was allowed to reach about 5.3 mmol/l and was kept stable The study group comprised 11 patients with type 1 diabetes for 120 min by adjusting the rate of a 20% dextrose infusion. and end-stage renal disease. There were 7 women and 4 men. Samples for glucose determination were drawn at 5-15-min Mean age was 42.9±2.9 years (median 38.0 years) and intervals. Plasma insulin was measured from fasting pretest duration of diabetes was 31.4±3.4 years (median 31.0 years). samples and from samples drawn during steady state at All subjects were C-peptide negative (<0.07 nmol/l ). Before 10-min intervals. Plasma steady-state glucose concentrations CAPD the recommended daily protein intake was 0.8 g/kg were 5.6±0.2, 5.4±0.1 and 5.3±0.4 mmol/l during preand during CAPD 1.2 g/kg. In addition, daily diet consisted CAPD, subcutaneous, and intraperitoneal insulin treatment of >200 g/day carbohydrates with moderate sodium and periods respectively (NS). Samples for HbA 1c , haemoglobin, potassium restriction. Individual adjustments were made urea, creatinine, albumin and serum lipids were drawn prior when necessary. CAPD treatment was conducted as four to initiation of the clamp study, separated immediately and daily exchanges of 2-litre bags containing 1.5% or 2.3% frozen to −70°C for later analysis. The patients kept records dextrose. Two patients required an increase in dialysis efficacy of their home blood glucose readings and noted when severe during the study period. During the study patients used hypoglycaemias required them to ask for assistance from antihypertensive drugs, nitrates, recombinant human erythro-another person. poetin, and a vitamin D analogue. No antihyperlipidaemic agents were used during the study. The studies were uniformly Analytical methods scattered throughout the four seasons. All patients gave written informed consent after explanation of the purpose of Plasma glucose was analysed with a glucose oxidase method the study. The study protocol was approved by the Ethical (Beckman II, Fullerton, CA, USA). Serum insulin was Committee of Tampere University Hospital.
analysed by RIA (Phasedeph, Pharmacia, Sweden). HbA 1c was determined by high-performance liquid chromatography Protocol (Mono-S, Pharmacia, Sweden). Serum lipids were measured with an enzymatic method and HDL-cholesterol after extracMetabolic studies were performed in all 11 patients after tion with dextran sulphate. Other analytical procedures were subcutaneous and intraperitoneal insulin usage (two-phase done with an automated selective chemistry analyser using study). Six patients were additionally studied at the initiation routine applications ( Kone-C, Helsinki, Finland). of CAPD ( three-phase study). During CAPD all patients were first treated with subcutaneous and then with intraperiCalculations toneal insulin. In the two-phase study the mean duration of CAPD with subcutaneous insulin was 5.6±1.4 months The glucose disposal rate (M ) was calculated as the mean (median 3.0 months) and with intraperitoneal insulin 2.9±0.2 of the final 60 min of the clamp. The insulin sensitivity index (median 3.0 months). Subcutaneous treatment period in the is expressed as M divided by insulin increment above the three-phase study was 3.0±0.0 months (median 3.0 months) basal level (M/DIRI *1000). Values are expressed as means and intraperitoneal insulin period 3.1±0.1 months (median ±SEM. Statistical evaluation was done with Student's t test 3.0 months).
for paired data (BMDP Solo, Los Angeles, USA). During the subcutaneous therapy period patients administered regular insulin (ActrapidA, NovoNordisk, Helsinki, Finland) three times daily prior to meals and NPH insulin Results ( ProtaphaneA, NovoNordisk) in the evenings. After switching to intraperitoneal insulin patients injected regular insulin into the dialysis bags four times per day prior to fluid Three-phase study exchange. Three of these daily doses were equal but the Results of the six patients are shown in Table 1 . During nightly dose was reduced by 20%.
CAPD treatment the subcutaneous insulin dose
Blood glucose home monitoring was carried out before insulin injections four times per day at least once a week and increased from 30.7±2.4 to 35.2±3.6 U/day (P= Table 1 Figure 1) , increased glucose disposal rate from itivity (M/DIRI ) values were 5.57±1.13, 7.98±1.95, and 8.70±2.17 mg/kg/min/pmol/l ( pre-CAPD, subcutaneous and intraperitoneal insulin periods). Our findings support and extend those findings. The continuation of CAPD for over 3 months improved glucose disposal rate by 39%, which was further improved by injecting insulin into intraperitoneal space. The clamp method measures principally glucose uptake by peripheral tissues and muscle represent over 90% of this uptake [16 ] . Endogenous glucose production was not measured in this study and total glucose uptake is not possible to calculate. Also we did not construct an insulin dose-response curve. However, with a rather high insulin concentration of approximately 1140 pmol/l it can be assumed that endogenous glucose production was almost completely suppressed [13] . In a previous study a plasma insulin concentration of 1200 pmol/l induced over 50% of the maximal suppression in all uraemic diabetic patients [5 ] . Accordingly, in this study glucose disposal rate measured with supraphysiological insulin concentrations reflects mainly insulin sensitivity in muscle tissues. control by subcutaneous insulin leads to elevated peripheral insulin concentrations [3] . Peripheral hyperinsu-7.10±0.84 to 8.12±0.83 mg/kg/min (P=0.002, linaemia has been shown to induce and maintain Figure 2 ) and increased insulin sensitivity index insulin resistance [17 ] . When CAPD treatment was ( M/DIRI) from 6.61±0.93 to 7.54±1.00 mg/kg/min/ initiated in our study, subcutaneous insulin administrapmol/l after intraperitoneal insulin period (P=0.001). tion was continued. No significant fasting plasma Intraperitoneal insulin resulted in lower fasting plasma insulin changes occurred. Neither can any changes in insulin levels than subcutaneous insulin ( 104.8±15.8 portal insulin concentration be assumed. It is unlikely and 87.9±16.3 pmol/l respectively, P=0.052).
that changes in insulin concentration can explain the Switching from subcutaneous to intraperitoneal improved glucose disposal rate. After switching from insulin administration increased serum cholesterol by subcutaneous to intraperitoneal insulin delivery, nor-4%, LDL-cholesterol by 16%, and triglycerides by 19% malization of the peripheral insulin profile and portal/ ( Table 2 ). The HDL-cholesterol concentration showed peripheral insulin gradient [3 ] may explain, at least to a 33% reduction from 1.35±0.15 to 0.90±0.04 mmol/l some extent, the improvement in insulin sensitivity. (P=0.009) and the LDL/HDL-cholesterol ratio Ingested carbohydrates improve insulin sensitivity increased significantly (from 2.70±0.34 to 4.31±0.58, [18] although this has not been possible to show P=0.005).
conclusively in short-term studies [19] . During CAPD One episode of peritonitis was recorded during intra-the patient absorbs approximately 100 g of glucose per peritoneal insulin treatment. After the study, patients day through the peritoneal membranes [1]. It is poswere allowed to select their insulin treatment mode. sible that this can alter hepatic handling of gluconeoNine preferred intraperitoneal while two returned to genic substrates and thus improve insulin sensitivity in subcutaneous because of nauseous feeling during intra-peripheral tissues [20 ] . peritoneal insulin.
Glycaemic control did not improve when CAPD with subcutaneous insulin was used compared to the Discussion predialysis situation, in fact, HbA 1c rose. Better glycaemic control in diabetic patients has been linked to improved glucose disposal rate [14 ] . During intraperiInsulin replacement through the intraperitoneal route is easily achieved with patients on CAPD. It offers toneal insulin delivery this can partly adopt the Insulin therapy and CAPD 149 improvement in insulin sensitivity. Initiation of CAPD patients undergoing intraperitoneal insulin therapy [10] . In this study qualitative lipid analysis was not favours anabolic metabolism and thus improves the uraemic state. Increased appetite and the glucose load done and thus no conclusions can be drawn.
We conclude that the initiation of CAPD therapy from the dialysate brings more energy than is possible to control with a modest increase in subcutaneous improved insulin sensitivity among limited number of type 1 diabetic patients with ESRD. This was further insulin dose. Fear of severe hypoglycaemic episodes may have hindered patients from increasing the insulin enhanced by switching from subcutaneous to intraperitoneal insulin administration. Intraperitoneal insulin dose sufficiently. It has been suggested that during intraperitoneal insulin the amplitude of daily glucose resulted in better glycaemic control. Quantitative lipid changes with intraperitoneal insulin showed decreased fluctuations is limited [4 ] and that the recognition of hypoglycaemic symptoms better than during subcuta-serum HDL-cholesterol and increased LDL/HDL-cholesterol ratio. Whether this finding has significance in neous insulin [21 ] . Our findings support these observations. the long-term survival rate of these subjects needs further study. Malnutrition is an important clinical problem in dialysis patients, and serum albumin is often used as
